Background: Current guidelines recommend placing an implantable cardiac defibrillator for patients with cardiac sarcoidosis and a severely impaired left ventricular ejection fraction (LVEF) of ≤35%. In this study, we determined the association between mild or moderate LVEF impairment and fatal ventricular arrhythmic event (FVAE). Methods and Results: We retrospectively analyzed 401 patients with cardiac sarcoidosis without sustained ventricular arrhythmia at diagnosis. The primary end point was an FVAE, defined as the combined endpoint of documented ventricular tachycardia or ventricular fibrillation and sudden cardiac death. Two cutoff points for LVEF were used: a sex‐specific lower threshold of normal range of LVEF (52% for men and 54% for women) and an LVEF of 35%, which is used in the current guidelines. During a median follow‐up of 3.2 years, 58 FVAEs were observed, and the 5‐ and 10‐year estimated incidences of FVAEs were 16.8% and 23.0%, respectively. All patients were classified into 3 groups according to LVEF: impaired LVEF group, mild to moderate impairment of LVEF group, and maintained LVEF group. Multivariable competing risk analysis showed that both the impaired LVEF group (hazard ratio [HR], 3.24 [95% CI, 1.49–7.04]) and the mild to moderate impairment of LVEF group (HR, 2.16 [95% CI, 1.04–4.46]) were associated with a higher incidence of FVAEs than the maintained LVEF group after adjustment for covariates. Conclusions: Patients with cardiac sarcoidosis are at a high risk of FVAEs, regardless of documented ventricular arrhythmia at the time of diagnosis. In patients with cardiac sarcoidosis, mild to moderate impairment of LVEF is associated with FVAEs.
1 November 2024 in Circulation: Cardiovascular Imaging
BACKGROUND: Accurate assessment of left ventricular filling pressure in patients with atrial fibrillation or flutter (AF) remains difficult. A novel 2-dimensional scoring system, visually assessing time difference between mitral valve and tricuspid valve opening (VMT) score, based on temporal analysis of early diastolic valve opening, could be applied to these patients. We aimed to determine the usefulness of the VMT score in patients with AF. METHODS: We analyzed 119 consecutive patients with AF who underwent cardiac catheterization as a derivation cohort. The diagnostic performance of the VMT score was further evaluated in an external data set containing 189 patients with AF. Elevated left ventricular filling pressure was defined as a mean pulmonary arterial wedge pressure ≥15 mm Hg. The time sequence of atrioventricular valve opening was visually assessed and scored (0, tricuspid valve first; 1, simultaneous; 2, mitral valve first). When the inferior vena cava was dilated, 1 point was added, and the VMT score was finally graded as 0 to 3. Conventional Doppler parameters to estimate left ventricular filling pressure were also measured. RESULTS: Pulmonary arterial wedge pressure was elevated with an increase in the VMT score (0: 10±3, 1: 13±5, 2: 22±7, 3: 27±6 mm Hg; P <0.001), resulting in a significant rise in pulmonary arterial wedge pressure from VMT score 1 to 2. VMT≥2 predicted elevated pulmonary arterial wedge pressure with an accuracy of 87%, and the diagnostic accuracy of the VMT score was significantly higher than that of conventional Doppler parameters ( C index, 0.88 versus 0.54–0.68; P <0.001). In addition, VMT ≥2 showed an incremental predictive value over plasma brain natriuretic peptide levels ( C index, 0.79–0.93; P <0.001). In the external validation cohort, VMT≥2 demonstrated acceptable accuracy of 72%. CONCLUSIONS: VMT scoring was a useful echocardiographic marker of elevated left ventricular filling pressure and had an incremental benefit over practical biomarkers in patients with AF.
6 January 2026 in Journal of the American Heart Association
Background: The prognostic value of handgrip strength, a simple and reliable indicator of sarcopenia, in older patients with heart failure remains uncertain. This study aimed to investigate the prognostic value of handgrip strength in hospitalized patients aged ≥65 years with heart failure. Methods: This post hoc analysis used data from FRAGILE‐HF (Prevalence and Prognostic Value of Physical and Social Frailty in Geriatric Patients Hospitalized for Heart Failure), a prospective, multicenter cohort study involving patients aged ≥65 years hospitalized for heart failure. Handgrip strength was measured before discharge using a dynamometer, with the higher value from 2 trials recorded. Measurements were standardized by dividing 28 and 18 kg for men and women, respectively, per 2019 Asian Working Group for Sarcopenia criteria. Patients were categorized into tertiles (tertile 1, highest; tertile 2, middle; and tertile 3, lowest). The primary outcome was 2‐year all‐cause death. Results: Among 1269 patients (median age, 81 years; 57.1% men), 275 died during follow‐up. Kaplan–Meier analysis revealed a stepwise increase in death across the lowest handgrip tertiles, which remained significant after multivariable adjustment (tertile 2 versus tertile 1: hazard ratio [HR], 1.64 [95% CI, 1.14–2.37]; P =0.007; tertile 3 versus tertile 1: HR, 2.03 [95% CI, 1.42–2.90]; P <0.001). The analysis using a linear model showed that the prognostic impact of reduced handgrip strength increased with age. Conclusions: Lower handgrip strength was independently associated with death in older patients with heart failure, with stronger associations observed in the oldest patients. These findings highlight the additional prognostic value of handgrip strength beyond conventional risk factors. Registration: URL: center6.umin.ac.jp ; Unique Identifier: UMIN000023929.